Skip to main content
    I

    Incyte Corporation (INCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $120.27
    -0.70 (-0.58%)

    Market Cap: $24.66B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Incyte Corporation (INCY) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Incyte (INCY) trades at 45.9x trailing earnings and 4.1x sales. Its P/E of 45.9x is above its 5-year median of 24.9x. Its forward P/E is 13.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 235.0% higher over the next year. Its free cash flow yield is 2.8%.

    MultipleValue
    P/E (trailing)45.9x
    Forward P/E13.7x
    Price to sales4.1x
    Price to book4.3x
    EV/EBITDA28.7x
    Price to FCF35.7x
    EV/FCF31.0x
    PEG10.8
    FCF yield2.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 25.5% below 5.5x and its P/B is 10.4% below 4.8x.

    MultipleCurrent5-year median10-year median
    P/E45.9x24.9xN/A
    P/S4.1x3.9x5.5x
    P/B4.3x3.9x4.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 14.5x in 2025 to 185.7x in 2016. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$98.7714.5x3.8x3.9x
    2024$69.0752.3x3.4x4.0x
    2023$62.7917.8x3.8x2.7x
    2022$80.3228.9x5.3x4.1x
    2021$73.4026.7x5.4x4.3x
    2020$86.98N/A7.1x7.4x
    2019$87.3230.7x8.7x7.3x
    2018$63.5961.7x7.2x7.1x
    2017$94.71N/A12.6x12.3x
    2016$100.27185.7x17.2x46.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About INCY

    What is INCY's forward P/E ratio?

    Incyte has a forward P/E ratio of 13.7x.

    Is INCY stock overvalued?

    GNG's valuation label for INCY is Overvalued.

    What is INCY's price to sales ratio?

    Incyte has a price to sales ratio of 4.1x.

    What is Incyte's average P/E ratio over 5 years?

    Incyte's median P/E over the last 5 years is 24.9x, from 60 month-end values through Oct 2026.

    What is INCY's PEG ratio?

    Incyte has a PEG ratio of 10.8.